IQVIA Holdings Inc. (NYSE:IQV) Holdings Lifted by Cetera Investment Advisers

Cetera Investment Advisers boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,681 shares of the medical research company’s stock after buying an additional 8,524 shares during the quarter. Cetera Investment Advisers’ holdings in IQVIA were worth $12,814,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Continuum Advisory LLC boosted its stake in IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company’s stock valued at $354,000 after buying an additional 64 shares in the last quarter. Ballentine Partners LLC boosted its stake in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after buying an additional 69 shares in the last quarter. ST Germain D J Co. Inc. boosted its stake in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in IQVIA by 10.7% during the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company’s stock valued at $182,000 after buying an additional 90 shares in the last quarter. Finally, Private Trust Co. NA lifted its holdings in shares of IQVIA by 22.4% during the first quarter. Private Trust Co. NA now owns 536 shares of the medical research company’s stock valued at $94,000 after purchasing an additional 98 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.7%

IQV opened at $194.41 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The business has a 50-day moving average of $159.17 and a 200-day moving average of $170.16. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $33.05 billion, a PE ratio of 28.13, a price-to-earnings-growth ratio of 2.17 and a beta of 1.30.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the business earned $2.64 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Barclays upped their target price on IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. JPMorgan Chase & Co. reduced their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, May 19th. HSBC downgraded IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the company from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a report on Thursday, May 22nd. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $228.62.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.